1. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease.
- Author
-
Zhang H, Targher G, Byrne CD, Kim SU, Wong VW, Valenti L, Glickman M, Ponce J, Mantzoros CS, Crespo J, Gronbaek H, Yang W, Eslam M, Wong RJ, Machado MV, Yu ML, Ghanem OM, Okanoue T, Liu JF, Lee YH, Xu XY, Pan Q, Sui M, Lonardo A, Yilmaz Y, Zhu LY, Moreno C, Miele L, Lupsor-Platon M, Zhao L, LaMasters TL, Gish RG, Zhang H, Nedelcu M, Chan WK, Xia MF, Bril F, Shi JP, Datz C, Romeo S, Sun J, Liu D, Sookoian S, Mao YM, Méndez-Sánchez N, Wang XY, Pyrsopoulos NT, Fan JG, Fouad Y, Sun DQ, Giannini C, Chai J, Xia ZF, Jun DW, Li GJ, Treeprasertsuk S, Li YX, Cheung TT, Zhang F, Goh GB, Furuhashi M, Seto WK, Huang H, Di Sessa A, Li QH, Cholongitas E, Zhang L, Silveira TR, Sebastiani G, Adams LA, Chen W, Qi X, Rankovic I, De Ledinghen V, Lv WJ, Hamaguchi M, Kassir R, Müller-Wieland D, Romero-Gomez M, Xu Y, Xu YC, Chen SY, Kermansaravi M, Kuchay MS, Lefere S, Parmar C, Lip GYH, Liu CJ, Åberg F, Lau G, George J, Sarin SK, Zhou JY, and Zheng MH
- Abstract
Background: With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11., Methods: Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members., Results: A total of 890 international experts in various fields from 61 countries responded to the survey. We also achieved full coverage of provincial-level administrative regions in China. 77.1% of respondents agreed that MAFLD should be represented in ICD-11 by updating NAFLD, with no significant regional differences (77.3% in Asia and 76.6% in non-Asia, p = 0.819). Over 80% of respondents agreed or somewhat agreed with the need to assign specific codes for progressive stages of MAFLD (i.e. steatohepatitis) (92.2%), MAFLD combined with comorbidities (84.1%), or MAFLD subtypes (i.e., lean, overweight/obese, and diabetic) (86.1%)., Conclusions: This global survey by a collaborative panel of clinical, coding, health management and policy experts, indicates agreement that MAFLD should be coded in ICD-11. The data serves as a foundation for corresponding adjustments in the ICD-11 revision., (© 2024. Asian Pacific Association for the Study of the Liver.)
- Published
- 2024
- Full Text
- View/download PDF